J. Thomas Haskins

2.5k total citations
33 papers, 2.0k citations indexed

About

J. Thomas Haskins is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, J. Thomas Haskins has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cellular and Molecular Neuroscience, 10 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in J. Thomas Haskins's work include Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers), Bipolar Disorder and Treatment (7 papers) and Receptor Mechanisms and Signaling (7 papers). J. Thomas Haskins is often cited by papers focused on Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers), Bipolar Disorder and Treatment (7 papers) and Receptor Mechanisms and Signaling (7 papers). J. Thomas Haskins collaborates with scholars based in United States, Belgium and Canada. J. Thomas Haskins's co-authors include Eric A. Muth, John A. Moyer, G. E. M. Husbands, E.B. Sigg, Terrance H. Andree, Robert L. DuPont, William O. Dawson, Jonathan R. T. Davidson, Susan Nielsen and James E. Blankenship and has published in prestigious journals such as JAMA, American Journal of Psychiatry and Journal of Neurophysiology.

In The Last Decade

J. Thomas Haskins

33 papers receiving 1.8k citations

Peers

Countries citing papers authored by J. Thomas Haskins

Since Specialization

Citations

This map shows the geographic impact of J. Thomas Haskins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Thomas Haskins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Thomas Haskins more than expected).

Fields of papers citing papers by J. Thomas Haskins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Thomas Haskins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Thomas Haskins. The network helps show where J. Thomas Haskins may publish in the future.

Co-authorship network of co-authors of J. Thomas Haskins

This figure shows the co-authorship network connecting the top 25 collaborators of J. Thomas Haskins. A scholar is included among the top collaborators of J. Thomas Haskins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Thomas Haskins. J. Thomas Haskins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health Care Resource Utilization and Costs in a Commercially Insured Population of Patients With Bipolar Disorder Type I and Frequent Psychiatric Interventions 2011 ·Clinical Therapeutics ·Erin Bagalman, Erik Muser, Jiyoon Choi, Emily Durden, Wayne Macfadden, J. Thomas Haskins, Riad Dirani	12
2	Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms 2011 ·BMC Psychiatry ·Wayne Macfadden, Caleb M. Adler, Ibrahim Turkoz, J. Thomas Haskins, Norris Turner, Larry Alphs	19
3	Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale 2010 ·Journal of Psychiatric Practice ·(unknown), Jeffrey Veach, Wayne Macfadden, J. Thomas Haskins, John P. Docherty, Jean‐Pierre Lindenmayer	13
4	Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions 2010 ·Journal of Medical Economics ·J. Thomas Haskins, Wayne Macfadden, Norris Turner, Concetta Crivera, Riad Dirani, Larry Alphs, Kenneth Gersing, Bruce M. Burchett	5
5	Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia 2010 ·International Clinical Psychopharmacology ·Wayne Macfadden, Cynthia A. Bossie, Ibrahim Turkoz, J. Thomas Haskins	18
6	Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population 2010 ·Journal of Medical Economics ·Emily Durden, Erin Bagalman, Erik Muser, Jiyoon Choi, Concetta Crivera, Riad Dirani, Wayne Macfadden, J. Thomas Haskins	9
7	A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse frequently 2009 ·Bipolar Disorders ·Wayne Macfadden, Larry Alphs, J. Thomas Haskins, Norris Turner, Ibrahim Turkoz, Cynthia A. Bossie, Mary J. Kujawa, Ramy Mahmoud	90
8	Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder 2000 ·American Journal of Psychiatry ·Karl Rickels, Mark H. Pollack, David V. Sheehan, J. Thomas Haskins	181
9	Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder 2000 ·JAMA ·Alan J. Gelenberg, R. Bruce Lydiard, Richard L. Rudolph, (unknown), J. Thomas Haskins, Eliseo Salinas	209
10	Efficacy, Safety, and Tolerability of Venlafaxine Extended Release and Buspirone in Outpatients With Generalized Anxiety Disorder 1999 ·The Journal of Clinical Psychiatry ·Jonathan R. T. Davidson, Robert L. DuPont, William O. Dawson, J. Thomas Haskins	225
11	WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors 1993 ·European Journal of Pharmacology ·Allan Fletcher, David J. Bill, (unknown), Ian A. Cliffe, (unknown), (unknown), J. Thomas Haskins, Deborah E. Jones, Howard L. Mansell, (unknown)	198
12	Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine 1991 ·Drug Development Research ·Eric A. Muth, John A. Moyer, J. Thomas Haskins, Terrance H. Andree, G. E. M. Husbands	174
13	Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents 1989 ·Journal of Medicinal Chemistry ·Magid Abou‐Gharbia, John A. Moyer, Usha Patel, Michael R. Webb, Guy A. Schiehser, Terrance H. Andree, J. Thomas Haskins	36
14	Preclinical profile of the pyrimidinylpiperazinyl imide compound WY‐47,846: A potential anxiolytic 1989 ·Drug Development Research ·J. Thomas Haskins, John A. Moyer, Terrance H. Andree, Eric A. Muth, Magid Abou‐Gharbia	17
15	Biochemical and electrophysiological studies of the psychotropic compound, amperozide 1987 ·Brain Research Bulletin ·J. Thomas Haskins, Eric A. Muth, Terrance H. Andree	30
16	Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative 1986 ·Biochemical Pharmacology ·Eric A. Muth, J. Thomas Haskins, John A. Moyer, G. E. M. Husbands, Susan Nielsen, E.B. Sigg	323
17	Action of estrogen and mechanical vaginocervical stimulation on the membrane excitability of hypothalamic and midbrain neurons 1983 ·Brain Research Bulletin ·J. Thomas Haskins, Robert L. Moss	30
18	Differential effects of morphine, dopamine and prolactin administered iontophoretically on arcuate-ventromedial hypothalamic neurons 1983 ·Brain Research ·J. Thomas Haskins, Robert L. Moss	22
19	Iontophoresis of Morphine into the Arcuate Nucleus: Effects on Dopamine Concentrations in Hypophysial Portal Plasma and Serum Prolactin Concentrations* 1981 ·Endocrinology ·J. Thomas Haskins, Gary A. Gudelsky, Robert L. Moss, John C. Porter	65
20	Initial report on combined in vivo single cell recording and intracellular staining 1981 ·Brain Research Bulletin ·J. Thomas Haskins, Robert L. Moss	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact